iCAD wins FDA approvals
The FDA has cleared for marketing three computer-assisted detection technologies developed by iCAD: iDM, which works with Fischer Imaging's SenoScan full-field digital mammography system; iAD, a full-featured stand-alone unit, and iQ, a low-cost
The FDA has cleared for marketing three computer-assisted detection technologies developed by iCAD: iDM, which works with Fischer Imaging's SenoScan full-field digital mammography system; iAD, a full-featured stand-alone unit, and iQ, a low-cost stand-alone unit. Following the FDA approvals, iCAD and Fischer announced an expanded development and distribution agreement that includes the new iAD product, which reads digitized mammography films. iCAD, located in Nashua, NH, plans to market the device to women's health centers and breast clinics that perform fewer than 20 mammography procedures a day.
Contrast-Enhanced Mammography Study Reveals 24 Percent Lower Sensitivity with Moderate/Marked BPE
April 30th 2025In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.
